Targeting phosphoinositide 3-kinase signalling in lung cancer

Critical Reviews in Oncology/Hematology

Volumn 80, Issue 2, 2011, Pages 278-290

  Wojtalla, Anna ^a   Arcaro, Alexandre ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Akt; Mammalian target of rapamycin; Non small cell lung cancer; Phosphoinositide 3 kinase; Small cell lung cancer

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; 2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; GEFITINIB; METFORMIN; MK 2206; NICOTINE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; SELUMETINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VINORELBINE DITARTRATE; XL 147;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FATIGUE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALIGNANT TRANSFORMATION; MONOTHERAPY; NAUSEA; NONHUMAN; PROTEIN TARGETING; PTEN GENE; REVIEW; SIGNAL TRANSDUCTION; SMOKING; SOLID TUMOR; TUMOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; ENZYME INHIBITORS; HUMANS; LUNG; LUNG NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION; SMALL CELL LUNG CARCINOMA;

EID: 79960920361     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.01.007     Document Type: Review

References (129)

1. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010.
2. Vandenbroucke E., De Ryck F., Surmont V., et al. What is the role for surgery in patients with stage III non-small cell lung cancer?. Curr Opin Pulm Med 2009, 15(4):295-302.
3. Robinson C.G., Bradley J.D. The treatment of early-stage disease. Semin Radiat Oncol 2010, 20(3):178-185.
4. Molina J.R., Adjei A.A., Jett J.R. Advances in chemotherapy of non-small cell lung cancer. Chest 2006, 130(4):1211-1219.
5. Jackman D.M., Johnson B.E. Small-cell lung cancer. Lancet 2005, 366(9494):1385-1396.
6. Demedts I.K., Vermaelen K.Y., van Meerbeeck J.P. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Eur Respir J 2010, 35(1):202-215.
7. Sculier J.P., Berghmans T., Meert A.P. Update in lung cancer and mesothelioma 2009. Am J Respir Crit Care Med 2010, 181(8):773-781.
8. Hodkinson P.S., Mackinnon A., Sethi T. Targeting growth factors in lung cancer. Chest 2008, 133(5):1209-1216.
9. Pisick E., Jagadeesh S., Salgia R. Receptor tyrosine kinases and inhibitors in lung cancer. ScientificWorldJournal 2004, 4:589-604.
10. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009, 9(8):550-562.
11. Garcia-Echeverria C., Sellers W.R. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008, 27(41):5511-5526.
12. Liu P., Cheng H., Roberts T.M., et al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009, 8(8):627-644.
13. Carlisle D.L., Liu X., Hopkins T.M., et al. Nicotine activates cell-signaling pathways through muscle-type and neuronal nicotinic acetylcholine receptors in non-small cell lung cancer cells. Pulm Pharmacol Ther 2006.
14. Tsurutani J., Castillo S.S., Brognard J., et al. Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells. Carcinogenesis 2005, 26(7):1182-1195.
15. West K.A., Brognard J., Clark A.S., et al. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest 2003, 111(1):81-90.
16. Gustafson A.M., Soldi R., Anderlind C., et al. Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci Transl Med 2010, 2(26):26ra25.
17. Sun X., Ritzenthaler J.D., Zhong X., et al. Nicotine stimulates PPARbeta/delta expression in human lung carcinoma cells through activation of PI3K/mTOR and suppression of AP-2alpha. Cancer Res 2009, 69(16):6445-6453.
18. Xin M., Deng X. Nicotine inactivation of the proapoptotic function of Bax through phosphorylation. J Biol Chem 2005, 280(11):10781-10789.
19. Jin Z., Gao F., Flagg T., et al. Nicotine induces multi-site phosphorylation of Bad in association with suppression of apoptosis. J Biol Chem 2004, 279(22):23837-23844.
20. Lin X., Böhle A.S., Dohrmann P., et al. Overexpression of phosphatidylinositol 3-kinase in human lung cancer. Langenbecks Arch Surg 2001, 386(4):293-301.
21. Massion P.P., Taflan P.M., Shyr Y., et al. Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med 2004, 170(10):1088-1094.
22. Yamamoto H., Shigematsu H., Nomura M., et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 2008, 68(17):6913-6921.
23. Akca H., Tani M., Hishida T., et al. Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells. Lung Cancer 2006, 54(1):25-33.
24. Sordella R., Bell D.W., Haber D.A., et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305(5687):1163-1167.
25. Zinda M.J., Johnson M.A., Paul J.D., et al. AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon. Clin Cancer Res 2001, 7(8):2475-2479.
26. Soung Y.H., Lee J.W., Nam S.W., et al. Mutational analysis of AKT1, AKT2 and AKT3 genes in common human carcinomas. Oncology 2006, 70(4):285-289.
27. Brognard J., Clark A.S., Ni Y., et al. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001, 61(10):3986-3997.
28. Chun K.H., Kosmeder J.W., Sun S., et al. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Natl Cancer Inst 2003, 95(4):291-302.
29. Lee S.H., Kim H.S., Park W.S., et al. Non-small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study. APMIS 2002, 110(7-8):587-592.
30. Tsao A.S., McDonnell T., Lam S., et al. Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol Biomarkers Prev 2003, 12(7):660-664.
31. Tsurutani J., Steinberg S.M., Ballas M., et al. Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma. Lung Cancer 2007, 55(1):115-121.
32. Balsara B.R., Pei J., Mitsuuchi Y., et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004, 25(11):2053-2059.
33. David O., Jett J., LeBeau H., et al. Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res 2004, 10(20):6865-6871.
34. Tsurutani J., Fukuoka J., Tsurutani H., et al. Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol 2006, 24(2):306-314.
35. Marsit C.J., Zheng S., Aldape K., et al. PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol 2005, 36(7):768-776.
36. Singhal S., Amin K.M., Kruklitis R., et al. Differentially expressed apoptotic genes in early stage lung adenocarcinoma predicted by expression profiling. Cancer Biol Ther 2003, 2(5):566-571.
37. Soria J.C., Lee H.Y., Lee J.I., et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 2002, 8(5):1178-1184.
38. David O. Akt and PTEN: new diagnostic markers of non-small cell lung cancer?. J Cell Mol Med 2001, 5(4):430-433.
39. Kokubo Y., Gemma A., Noro R., et al. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer 2005, 92(9):1711-1719.
40. Tang J.M., He Q.Y., Guo R.X., et al. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 2006, 51(2):181-191.
41. Teng D.H., Hu R., Lin H., et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 1997, 57(23):5221-5225.
42. Forgacs E., Biesterveld E.J., Sekido Y., et al. Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene 1998, 17(12):1557-1565.
43. Forgacs E., Zöchbauer-Müller S., Oláh E., et al. Molecular genetic abnormalities in the pathogenesis of human lung cancer. Pathol Oncol Res 2001, 7(1):6-13.
44. Yokomizo A., Tindall D.J., Drabkin H., et al. PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene 1998, 17(4):475-479.
45. Han S., Khuri F.R., Roman J. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res 2006, 66(1):315-323.
46. Conde E., Angulo B., Tang M., et al. Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling. Clin Cancer Res 2006, 12(3 Pt. 1):710-717.
47. Wislez M., Spencer M.L., Izzo J.G., et al. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res 2005, 65(8):3226-3235.
48. Yang Y., Iwanaga K., Raso M.G., et al. Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer. PLoS One 2008, 3(5):e2220.
49. Konstantinidou G., Bey E.A., Rabellino A., et al. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res 2009, 69(19):7644-7652.
50. Engelman J.A., Chen L., Tan X., et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008, 14(12):1351-1356.
51. Sos M.L., Fischer S., Ullrich R., et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A 2009, 106(43):18351-18356.
52. Faber A.C., Li D., Song Y., et al. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A 2009, 106(46):19503-19508.
53. Sun S.Y., Rosenberg L.M., Wang X., et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005, 65(16):7052-7058.
54. Lee H.Y., Oh S.H., Suh Y.A., et al. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer. Clin Cancer Res 2005, 11(16):6065-6074.
55. Lee H.Y., Srinivas H., Xia D., et al. Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent pathways cooperate to maintain lung cancer cell survival. J Biol Chem 2003, 278(26):23630-23638.
56. Kikuchi J., Kinoshita I., Shimizu Y., et al. Simultaneous blockade of AP-1 and phosphatidylinositol 3-kinase pathway in non-small cell lung cancer cells. Br J Cancer 2008, 99(12):2013-2019.
57. Govindan R., Page N., Morgensztern D., et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006, 24(28):4539-4544.
58. Cooper S., Spiro S.G. Small cell lung cancer: treatment review. Respirology 2006, 11(3):241-248.
59. Shibata T., Kokubu A., Tsuta K., et al. Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer. Cancer Lett 2009, 283(2):203-211.
60. Voortman J., Lee J.H., Killian J.K., et al. Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc Natl Acad Sci U S A 2010.
61. Moore S.M., Rintoul R.C., Walker T.R., et al. The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway. Cancer Res 1998, 58(22):5239-5247.
62. Arcaro A., Khanzada U.K., Vanhaesebroeck B., et al. Two distinct phosphoinositide 3-kinases mediate polypeptide growth factor-stimulated PKB activation. EMBO J 2002, 21(19):5097-5108.
63. Blackhall F.H., Pintilie M., Michael M., et al. Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clin Cancer Res 2003, 9(6):2241-2247.
64. Tsurutani J., West K.A., Sayyah J., et al. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res 2005, 65(18):8423-8432.
65. Kraus A.C., Ferber I., Bachmann S.O., et al. In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways. Oncogene 2002, 21(57):8683-8695.
66. Belyanskaya L.L., Hopkins-Donaldson S., Kurtz S., et al. Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation. Int J Cancer 2005, 117(5):755-763.
67. Krystal G.W., Sulanke G., Litz J. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther 2002, 1(11):913-922.
68. Warshamana-Greene G.S., Litz J., Buchdunger E., et al. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin Cancer Res 2005, 11(4):1563-1571.
69. Warshamana-Greene G.S., Litz J., Buchdunger E., et al. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling. Mol Cancer Ther 2004, 3(5):527-535.
70. Ma P.C., Tretiakova M.S., Nallasura V., et al. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br J Cancer 2007, 97(3):368-377.
71. Wang W.L., Healy M.E., Sattler M., et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 2000, 19(31):3521-3528.
72. Chen Y.L., Law P.Y., Loh H.H. Inhibition of akt/protein kinase B signaling by naltrindole in small cell lung cancer cells. Cancer Res 2004, 64(23):8723-8730.
73. Yeh J., Litz J., Hauck P., et al. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt. Lung Cancer 2008, 60(2):166-174.
74. Folkes A.J., Ahmadi K., Alderton W.K., et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 2008, 51(18):5522-5532.
75. A study of the safety pharmacology of PI3-kinase inhibitor GDC-0941 in combination with paclityxel and carboplatin with or without bevacizumab in patients with advanced non-small cell lung cancer. Study May 14-June 1, 2010. Available from: http://www.clinicaltrials.gov/.
76. A study on the safety and pharmacology of GDC-0941 in combination with erlotinib in patients with advanced solid tumors. Study May 14-June 1, 2010. Available from: http://www.clinicaltrials.gov/.
77. Baird R.D., Kristeleit R., Sarker D., Olmos D., Sandhu S.K., Yan Y., et al. A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941. J Clin Oncol 2010, 28(Suppl.):7s. abstr 2613, Asco Annual Meeting, 2010.
78. Von Hoff D.D.L.P., Tibes R., Shapiro G., Weiss G.J., Ware J.A., et al. A first-in-human phase I study to evaluate the pan-PI3K inhibitors GDC-0941 administered QD or BID in patients with advanced solid tumors. J Clin Oncol 2010, 28(Suppl.):7s. abstr 2541, ASCO Annual Meeting, 2010.
79. Yao E., Zhou W., Lee-Hoeflich S.T., et al. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res 2009, 15(12):4147-4156.
80. Junttila T.T., Akita R.W., Parsons K., et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009, 15(5):429-440.
81. Salphati L., Wong H., Belvin M., et al. Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel PI3K inhibitor 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941). Drug Metab Dispos 2010.
82. Sutherlin D.P., Sampath D., Berry M., et al. Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer. J Med Chem 2010, 53(3):1086-1097.
83. Raynaud F.I., Eccles S.A., Patel S., et al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther 2009, 8(7):1725-1738.
84. O'Brien C., Wallin J.J., Sampath D., et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 2010.
85. Safety study of XL147 in combination with paclitaxel and carboplatin in adults with solid tumors. Study February 25, 2009-June 1, 2010. Available from: http://www.clinicaltrials.gov/.
86. Safety study of XL147 in combination with erlotinib in adults with solid tumors. Study October 20, 2008-June 1, 2010. Available from: http://www.clinicaltrials.gov/.
87. Edelmann G., Bedell C., Shapiro G., Pandya S.S., Kwak E.L., Scheffold C., et al. A phase I dole-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies. J Clin Oncol 2010, 28(Suppl.):7s. abstr 3004, ASCO Annual Meeting, 2010.
88. Beuvink I., Boulay A., Fumagalli S., et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005, 120(6):747-759.
89. Mabuchi S., Altomare D.A., Cheung M., et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 2007, 13(14):4261-4270.
90. Boulay A., Zumstein-Mecker S., Stephan C., et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004, 64(1):252-261.
91. Buck E., Eyzaguirre A., Brown E., et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 2006, 5(11):2676-2684.
92. Majumder P.K., Febbo P.G., Bikoff R., et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004, 10(6):594-601.
93. Ramalingam S.S., Harvey R.D., Saba N., et al. Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. Cancer 2010.
94. Hu L., Hofmann J., Lu Y., et al. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002, 62(4):1087-1092.
95. Soria J.C., Shepherd F.A., Douillard J.Y., et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 2009, 20(10):1674-1681.
96. Milton D.T., Riely G.J., Azzoli C.G., et al. Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer 2007, 110(3):599-605.
97. Price K.A., Azzoli C.G., Krug L.M., et al. Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. J Thorac Oncol 2010, 5(10):1623-1629.
98. A study of TS-1, cisplatin (CDDP) and RAD001 (Everolimus). Study March 30-June 1, 2010. Available from: http://www.clinicaltrials.gov/.
99. Lee S., Choi E.J., Jin C., et al. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 2005, 97(1):26-34.
100. Liu L.Z., Zhou X.D., Qian G., et al. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res 2007, 67(13):6325-6332.
101. Wu C., Wangpaichitr M., Feun L., et al. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer 2005, 4(1):25.
102. Marinov M., Ziogas A., Pardo O.E., et al. AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. Clin Cancer Res 2009, 15(4):1277-1287.
103. Stracke S., Ramudo L., Keller F., et al. Antiproliferative and overadditive effects of everolimus and mycophenolate mofetil in pancreas and lung cancer cells in vitro. Transplant Proc 2006, 38(3):766-770.
104. Pandya K.J., Dahlberg S., Hidalgo M., et al. A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol 2007, 2(11):1036-1041.
105. Temsirolimus and vinorelbine ditartrate in treating patients with unresectable or metastatic solid tumors. Study July 14, 2010. Available from: http://www.clinicaltrials.gov/.
106. Metformin and temsirolimus in treating patients with metastatic or unresectable solid tumor or lymphoma. Study July 14, 2010. Available from: http://www.clinicaltrials.gov/.
107. Everolimus, carboplatin, and etoposide in treating patients with small cell lung cancer or other advanced solid tumors. Study March 25-July 5, 2010. Available from: http://www.clinicaltrials.gov/.
108. Combination anticancer therapy of paclitaxel, everolimus for relapsed or refractory small cell lung, cancer. March 8-July 5, 2010. Available from: http://www.clinicaltrials.gov/.
109. Phase II TRial of RAD001 (Everolimus) in previously treated small cell lung cancer. Study April 3-July 5, 2010. Available from: http://www.clinicaltrials.gov/.
110. Tarhini A., Kotsakis A., Gooding W., et al. Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res 2010, 16(23):5900-5907.
111. Burris H., Rodon J., Sharma S., Herbst R.S., Tabernero J., Infante J.R., et al. First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. J Clin Oncol 2010, 28(Suppl.):7s. abstr 3005, ASCO Annual Meeting, 2010.
112. Cho D.C., Cohen M.B., Panka D.J., et al. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 2010.
113. Maira S.M., Stauffer F., Brueggen J., et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008, 7(7):1851-1863.
114. Serra V., Markman B., Scaltriti M., et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008, 68(19):8022-8030.
115. Bhatt A.P., Bhende P.M., Sin S.H., et al. Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood 2010, 115(22):4455-4463.
116. Zitzmann K., Rüden J., Brand S., et al. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett 2010, 295(1):100-109.
117. Dose defining study for MK-2206 combined with gefitinib in non-small cell lung cancer (NSCLC). Study June 17-July 5, 2010. Available from: http://www.clinicaltrials.gov/.
118. Hirai H., Sootome H., Nakatsuru Y., et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010, 9(7):1956-1967.
119. White D.A., Schwartz L.H., Dimitrijevic S., et al. Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001). J Thorac Oncol 2009, 4(11):1357-1363.
120. Duran I., Siu L.L., Oza A.M., et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006, 42(12):1875-1880.
121. Cherrin C., Haskell K., Howell B., et al. An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo. Cancer Biol Ther 2010, 9(7):493-503.
122. Luo Y., Shoemaker A.R., Liu X., et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther 2005, 4(6):977-986.
123. Crouthamel M.C., Kahana J.A., Korenchuk S., et al. Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin Cancer Res 2009, 15(1):217-225.
124. Meuillet E.J., Ihle N., Baker A.F., et al. In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316. Oncol Res 2004, 14(10):513-527.
125. Garofalo R.S., Orena S.J., Rafidi K., et al. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. J Clin Invest 2003, 112(2):197-208.
126. Brachmann S.M., Ueki K., Engelman J.A., et al. Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice. Mol Cell Biol 2005, 25(5):1596-1607.
127. Foukas L.C., Claret M., Pearce W., et al. Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 2006, 441(7091):366-370.
128. Jou S.T., Carpino N., Takahashi Y., et al. Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol Cell Biol 2002, 22(24):8580-8591.
129. Okkenhaug K., Bilancio A., Farjot G., et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 2002, 297(5583):1031-1034.